|Bid||47.93 x 900|
|Ask||47.94 x 1300|
|Day's range||47.82 - 48.43|
|52-week range||36.15 - 64.94|
|Beta (5Y monthly)||0.17|
|PE ratio (TTM)||39.33|
|Forward dividend & yield||1.40 (2.91%)|
|Ex-dividend date||25 Feb 2021|
|1y target est||62.35|
The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, BioNTech, Moderna and AstraZeneca
Ladies and gentlemen, thank you for standing by, and welcome to the FibroGen Fourth Quarter and Full Year 2020 Financial Results Conference Call. Joining me on today's are Enrique Conterno, our Chief Executive Officer; Dr. Percy Carter, our Chief Scientific Officer; Pat Cotroneo, our Chief Financial Officer; Dr. Mark Eisner, our Chief Medical Officer; Thane Wettig, our Chief Commercial Officer; Chris Chung, our Senior Vice President of China Operations; and Dr. Elias Kouchakji, our Senior Vice President of Clinical Development, Drug Safety, and Pharmacovigilance.
J&J's (JNJ) single shot COVID-19 vaccine gets FDA emergency use authorization. U.S. CDC Advisory Committee also recommends J&J's vaccine.